The approval covers IV and subcutaneous pembrolizumab and raises the TMB-H threshold from 10 to 13 mutations/megabase.

The University of Kansas Cancer Center The University of South Alabama, Mitchell Cancer Institute The University of Texas MD Anderson Cancer Center The Winthrop P. Rockefeller Cancer Institute at the ...

The FDA granted accelerated approval to dostarlimab (Jemperli) on October 19, 2026, for adults with stage II/III locally ...

Alongside urinary symptoms, the regimen can cause systemic effects such as chills, fever, and musculoskeletal pain. Eppie ...

Erika Hamilton, MD, breaks down liver monitoring, diarrhea, creatinine shifts, and oral adherence with maintenance tucatinib ...

Nogapendekin alfa inbakicept-pmln plus BCG now covers high-grade papillary-only disease, based on extrapolation from CIS ...

FDA approves imlunestrant plus abemaciclib for ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast cancer after endocrine therapy. The FDA has approved imlunestrant (Inluriyo) in ...

Oral vitamin C at 1000 mg daily for 12 months did not slow clonal growth in adults with clonal cytopenia of undetermined ...

NP Theresa Stukus and NP Nelli Zafman conclude the discussion by reflecting on the resources, practice changes, and ...

Eppie Bass, APRN, explains how nurses can counsel patients on flu-like symptoms vs warning signs with nogapendekin alfa inbakicept-pmln and BCG.

For MBC Awareness Day, an NP and a former ICU nurse living with metastatic breast cancer discuss repeat education, biomarker ...

Breast cancer survivors are increasingly asking their care teams about glucagon-like peptide-1 (GLP-1) receptor agonists, and two nurses at Winship Cancer Institute of Emory University say the most ...